ZA944934B - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
ZA944934B
ZA944934B ZA944934A ZA944934A ZA944934B ZA 944934 B ZA944934 B ZA 944934B ZA 944934 A ZA944934 A ZA 944934A ZA 944934 A ZA944934 A ZA 944934A ZA 944934 B ZA944934 B ZA 944934B
Authority
ZA
South Africa
Prior art keywords
pct
pharmaceutical formulation
new pharmaceutical
formulation
sec
Prior art date
Application number
ZA944934A
Other languages
English (en)
Inventor
Inga Siv Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA944934(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA944934B publication Critical patent/ZA944934B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA944934A 1993-07-09 1994-07-07 New pharmaceutical formulation ZA944934B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ZA944934B true ZA944934B (en) 1995-02-20

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA944934A ZA944934B (en) 1993-07-09 1994-07-07 New pharmaceutical formulation

Country Status (40)

Country Link
US (1) US5690960A (fr)
EP (1) EP0706378B1 (fr)
JP (1) JP3665334B2 (fr)
KR (1) KR100350203B1 (fr)
CN (1) CN1126946A (fr)
AT (1) ATE231719T1 (fr)
AU (1) AU681686B2 (fr)
BR (1) BR9406941A (fr)
CA (1) CA2166483C (fr)
CZ (1) CZ290323B6 (fr)
DE (1) DE69432076T2 (fr)
DK (1) DK0706378T3 (fr)
DZ (1) DZ1794A1 (fr)
EE (1) EE03148B1 (fr)
EG (1) EG22373A (fr)
ES (1) ES2191682T3 (fr)
FI (1) FI114008B (fr)
HK (1) HK1008299A1 (fr)
HR (1) HRP940386B1 (fr)
HU (1) HU226779B1 (fr)
IL (1) IL110189A0 (fr)
IS (1) IS2034B (fr)
LV (1) LV13140B (fr)
MA (1) MA23258A1 (fr)
MX (1) MX9405219A (fr)
MY (1) MY128809A (fr)
NO (1) NO315146B1 (fr)
NZ (1) NZ268694A (fr)
PL (1) PL175210B1 (fr)
RU (1) RU2138254C9 (fr)
SA (1) SA94150057B1 (fr)
SE (1) SE9302395D0 (fr)
SG (1) SG52365A1 (fr)
SI (1) SI0706378T1 (fr)
SK (1) SK281105B6 (fr)
TN (1) TNSN94078A1 (fr)
UA (1) UA43342C2 (fr)
WO (1) WO1995001783A1 (fr)
YU (1) YU49199B (fr)
ZA (1) ZA944934B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ES2222754T3 (es) 1998-11-18 2005-02-01 Astrazeneca Ab Procedimiento quimico mejorado, y formulacion farmaceutica.
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
CA2367669A1 (fr) * 1999-03-29 2000-10-05 American Home Products Corporation Systeme d'enrobage
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
ATE369857T1 (de) 1999-10-20 2007-09-15 Eisai R&D Man Co Ltd Methode zur stabilisierung von benzimidazol- verbindungen
AU5248601A (en) * 2000-05-15 2001-11-26 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
PT1459737E (pt) 2001-10-17 2012-11-26 Takeda Pharmaceutical Grânulos contendo um composto químico instável em meio ácido em concentração elevada
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
AU2003209534A1 (en) * 2002-03-08 2003-09-22 Bakulesh Mafatlal Khamar The method of treating tuberculosis
BR0313173A (pt) * 2002-08-02 2007-07-17 Ratiopharm Gmbh preparação farmacêutica que contém um composto de benzimidazol misto com celulose microcristalina, método para sua preparação, bem como uso da dita celulose microcristalina
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (fr) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Procede de preparation d'un sel magnesique d'omeprazole
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (fr) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Forme posologique a doses ppi multiples
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006067599A2 (fr) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazoles et leur procede de preparation
EP1845982A2 (fr) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Compositions de benzimidazole orales stables preparees par un procede de stratification non aqueux
EP2275088B2 (fr) * 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Procédé de fabrication de granulés
EP1934201A1 (fr) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
EP2068841B1 (fr) 2006-10-05 2018-09-26 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
WO2008057802A2 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (fr) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
WO2009137648A1 (fr) * 2008-05-09 2009-11-12 Aptapharma, Inc. Pastilles multicouches inhibant la pompe à protons
CA2736547C (fr) 2008-09-09 2016-11-01 Pozen Inc. Procede d'administration d'une composition pharmaceutique a un patient en ayant besoin
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
WO2012174102A2 (fr) 2011-06-14 2012-12-20 Medical Defense Technologies, Llc. Procédé et appareil de guidage de soins médicaux sur la base d'une fonction gastrique détectée
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2021153525A1 (fr) 2020-01-27 2021-08-05 東和薬品株式会社 Préparation orale d'ésoméprazole et procédé de production associé
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
NZ268694A (en) 1997-05-26
ES2191682T3 (es) 2003-09-16
CA2166483C (fr) 1997-09-16
CA2166483A1 (fr) 1995-01-19
FI960102A (fi) 1996-01-09
HU226779B1 (en) 2009-10-28
EG22373A (en) 2002-12-31
AU681686B2 (en) 1997-09-04
SG52365A1 (en) 1998-09-28
PL312441A1 (en) 1996-04-29
HK1008299A1 (en) 1999-05-07
LV13140B (en) 2004-08-20
YU49199B (sh) 2004-09-03
HRP940386A2 (en) 1997-02-28
RU2138254C1 (ru) 1999-09-27
ATE231719T1 (de) 2003-02-15
MA23258A1 (fr) 1995-04-01
US5690960A (en) 1997-11-25
HUT75306A (en) 1997-05-28
FI114008B (fi) 2004-07-30
FI960102A0 (fi) 1996-01-09
PL175210B1 (pl) 1998-11-30
CZ7096A3 (en) 1996-06-12
SK2196A3 (en) 1997-04-09
SA94150057B1 (ar) 2006-10-03
SE9302395D0 (sv) 1993-07-09
MY128809A (en) 2007-02-28
IS2034B (is) 2005-08-15
SK281105B6 (sk) 2000-12-11
NO315146B1 (no) 2003-07-21
AU7198294A (en) 1995-02-06
BR9406941A (pt) 1996-09-10
NO960067L (no) 1996-01-05
DZ1794A1 (fr) 2002-02-17
HU9503874D0 (en) 1996-02-28
YU43794A (sh) 1997-07-31
CZ290323B6 (cs) 2002-07-17
MX9405219A (es) 1995-01-31
EP0706378B1 (fr) 2003-01-29
EP0706378A1 (fr) 1996-04-17
UA43342C2 (uk) 2001-12-17
EE03148B1 (et) 1999-02-15
WO1995001783A1 (fr) 1995-01-19
TNSN94078A1 (fr) 1995-04-25
DE69432076T2 (de) 2003-10-16
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
KR100350203B1 (ko) 2002-12-28
SI0706378T1 (en) 2003-06-30
HRP940386B1 (en) 2003-10-31
CN1126946A (zh) 1996-07-17
JP3665334B2 (ja) 2005-06-29
DE69432076D1 (de) 2003-03-06
RU2138254C9 (ru) 2009-09-27
DK0706378T3 (da) 2003-05-05

Similar Documents

Publication Publication Date Title
EG22373A (en) New pharmaceutical formulation
MY112915A (en) Multiple unit tableted dosage form 1
GEP20012375B (en) Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
EP0793660A4 (fr) 1,1-dioxydes de 1,2,5-thiadiazolidin-3-one substitues en position 2, compositions et procede d'utilisation
ZA966163B (en) Novel galanthamine derivatives, process for the preparation thereof, their application as medical drugs, and pharmaceutical compositions containing said derivatives.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
JO1821B1 (en) New pharmaceutical product
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
JO1880B1 (en) Format 1 for multi-unit calibration discs
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them